Therapeutics Development NOFOs
DTMC Flagship NOFOs
- PAR-25-328: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
- PAR-25-329: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
- PAR-24-300: Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)
- PAR-24-299: Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
- PAR-23-253: Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
- PAR-24-064: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Other relevant NOFOs
- PAR-23-191: HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) (reissue)
- PAS-21-270: AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
- PA-21-205: Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
- PAR-21-320: NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
Request for Applications (RFA)
- RFA DA 25-057: Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required)
- RFA-DA-25-058 Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
- RFA-DA-25-060: High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
- RFA-DA-25-040: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
- RFA-DA-22-040: HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
Notices
- NOT-DA-26-004 - Notice of Special Interest (NOSI): Training Program in Application of Artificial Intelligence in Development of Treatment for Substance Use Disorders)
- NOT-DA-26-005 - Notice of Special Interest (NOSI): Application of Artificial Intelligence in Treatment Development for Substance Use Disorders
- NOT-DA-26-002 - Notice of Special Interest (NOSI): Model-informed Drug Development (MIDD) Approaches to Facilitate the Development of Therapeutics for Substance Use Disorders
- NOT-DA-25-032: Notice of Special Interest (NOSI): Discovery and Development of Natural Products to Treat Substance Use Disorders (SUDs)
- NOT-DA-24-002: Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment
- NOT-DA-24-001: Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine.
- NOT-DA-24-12: Xylazine: Understanding Its Use and the Consequences
- NOT-DA-21-19: Telehealth Strategies for Individuals with HIV and Substance Use Disorders
- NOT-DA-21-018: Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders
- NOT-DA-21-017: Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19
- NOT-DA-21-011: Effects of smoking and vaping on the risk and outcome of COVID-19 infection